The treatment of AD still remains an area of significant unmet need, with drugs that only target the symptoms of the disease. Therefore there is considerable need for disease-modifying therapies. The complex etiology of AD prompts scientists to develop multi-target strategies to combat causes and symptoms. To this aim we designed, synthesized and tested four new carbamates as dual cholinesterase-FAAH inhibitors. The dual activity of these compounds could lead to a potentially more effective treatment for the counteraction of AD progression, because they would allow regulation of both ACh and eCB signalling, and improve neuronal transmission and/or counteract neuroinflammation.
A. Rampa, M. Bartolini, A. Bisi, F. Belluti, S. Gobbi, V. Andrisano, et al. (2012). The first dual ChE/FAAH inhibitors: new perspectives for Alzheimer's disease?. ACS MEDICINAL CHEMISTRY LETTERS, 3, 182-186 [10.1021/ml200313p].
The first dual ChE/FAAH inhibitors: new perspectives for Alzheimer's disease?
RAMPA, ANGELA;BARTOLINI, MANUELA;BISI, ALESSANDRA;BELLUTI, FEDERICA;GOBBI, SILVIA;ANDRISANO, VINCENZA;
2012
Abstract
The treatment of AD still remains an area of significant unmet need, with drugs that only target the symptoms of the disease. Therefore there is considerable need for disease-modifying therapies. The complex etiology of AD prompts scientists to develop multi-target strategies to combat causes and symptoms. To this aim we designed, synthesized and tested four new carbamates as dual cholinesterase-FAAH inhibitors. The dual activity of these compounds could lead to a potentially more effective treatment for the counteraction of AD progression, because they would allow regulation of both ACh and eCB signalling, and improve neuronal transmission and/or counteract neuroinflammation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
